Letter to the Editor| Volume 90, P114-115, August 2021

Download started.


Use of hydroxychloroquine to control immune response and hypercoagulability in patients with primary antiphospholipid syndrome

      Dear Editor,


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Turiel M.
        • Sarzi-Puttini P.
        • Peretti R.
        • et al.
        Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study.
        Stroke. 2005; 36: 1490-1494
        • Finazzi G.
        • Marchioli R.
        • Brancaccio V.
        • et al.
        A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).
        J Thromb Haemostasis: JTH. 2005; 3: 848-853
        • Belizna C.
        Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome.
        Autoimmun Rev. 2015; 14: 358-362
        • Ruiz-Irastorza G.
        • Cuadrado M.J.
        • Ruiz-Arruza I.
        • et al.
        Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies.
        Lupus. 2011; 20: 206-218
        • Hsu C.Y.
        • Lin Y.S.
        • Su Y.J.
        • et al.
        Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study.
        Rheumatology (Oxford). 2017; 56: 2212-2221
        • Petri M.
        Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.
        Lupus. 1996; 5: S16-S22
        • Ruiz-Irastorza G.
        • Egurbide M.V.
        • Pijoan J.I.
        • et al.
        Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.
        Lupus. 2006; 15: 577-583
        • Wallace DJ.
        Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?.
        Arthritis Rheumatism. 1987; 30: 1435-1436
        • Tobaldini L.Q.
        • Arantes F.T.
        • Saraiva S.D.S.
        • et al.
        Circulating levels of tissue factor and the risk of thrombosis associated with antiphospholipid syndrome.
        Thromb Res. 2018; 171: 114-120
        • Saraiva Sda S.
        • Custódio I.F.
        • Mazetto Bde M.
        • et al.
        Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response.
        Thromb Res. 2015; 136: 1174-1178